Microbot Medical (NASDAQ: MBOT) secures US patent for LIBERTY system

Rhea-AI Filing Summary

Microbot Medical Inc. reported that the U.S. Patent and Trademark Office has granted it a patent covering a modular robotic surgical system with a base and multiple independently attachable tool-receiver units. The company explains that this patent may allow its LIBERTY device to be adapted over time for a wider range of endovascular procedures, which could substantially increase the total addressable market it seeks to reach. The patent also broadens Microbot’s intellectual property protection for the LIBERTY system portfolio, which now consists of 12 patents granted globally and 57 patent applications pending.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0000883975 0000883975 2025-08-20 2025-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2025

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 20, 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that the United States Patent and Trademark Office (“USPTO”) has granted the Company a patent, covering a modular robotic surgical system which includes a base and a plurality of tool-receiver units arranged as separate units and independently and interchangeably attachable to the base (the “Patent”).

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 8.01 Other Events.

The USPTO granted the Patent to the Company, which will potentially enable its LIBERTY device to be adapted in the future for a wider range of endovascular procedures, which would increase substantially the Total Addressable Market (TAM) the Company is aiming to penetrate. The Patent expands the Company’s intellectual property protection in the United States for its LIBERTY^® system portfolio, which now includes 12 patents granted globally and 57 patent applications pending.

Forward Looking Statements

This Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: August 20, 2025

FAQ

What did Microbot Medical (MBOT) disclose in this 8-K filing?

Microbot Medical disclosed that the U.S. Patent and Trademark Office granted the company a patent for a modular robotic surgical system related to its LIBERTY device.

How does the new USPTO patent relate to Microbot Medical’s LIBERTY system?

The patent covers a modular robotic surgical system with a base and independently attachable tool-receiver units, which may allow the LIBERTY device to be adapted for a wider range of endovascular procedures.

How could this patent affect Microbot Medical’s total addressable market?

Microbot Medical states that the patent could enable LIBERTY to be used in more endovascular procedures, which would substantially increase the total addressable market the company aims to penetrate.

What is the current size of Microbot Medical’s LIBERTY intellectual property portfolio?

According to the disclosure, the LIBERTY system portfolio now includes 12 patents granted globally and 57 patent applications pending.

Does the filing say whether the information is considered filed or furnished?

The company notes that the press release attached as Exhibit 99.1 and the information in Item 7.01 are being furnished and are not deemed filed for purposes of Section 18 of the Exchange Act.

Does Microbot Medical include any forward-looking statements in this disclosure?

Yes. The company notes that this section may contain forward-looking statements, including beliefs and expectations about future regulatory milestones, and cautions that actual results could differ due to numerous factors.